Gilead Sciences to buy Cell Design Labs for $567 million

Share

On Dec. 7, 2017, Gilead Sciences and its cell-therapy subsidiary Kite Pharma announced an agreement to acquire Cell Design Labs, a pre-clinical stage biotherapeutics company specializing in custom cell engineering.

In August, Novartis AG's Kymriah became the first CAR-T cell therapy to get US approval, signaling a new era in the treatment of cancer.

The Cell Design acquisition could expand Gilead's cell therapy capabilities beyond cancer. He is also Cell Design Labs' scientific founder as well as an investigator with the Howard Hughes Medical Institute. The company's lead preclinical compound targets multiple myeloma.

"Cell Design Labs' talented team of cell biology experts will augment and accelerate our work to bring forward new generations of CAR-T and T-cell receptor (TCR) therapies, building on our acquisition of Kite earlier this year and our efforts to improve care for people with advanced cancers", Gilead president and CEO John F. Milligan, Ph.D., said in a statement. Under the terms of the deal, Gilead will initially pay about $175 million and dole out the remaining $322 million to CDL shareholders, other than Kite, following the achievement of certain.

Emeryville, CA-based Cell Design Labs is based on the research of University of California, San Francisco, scientist Wendell Lim.

Throttle, on the other hand, is an on switch that modulates vehicle T activity using small molecules.

Cell Design is a logical next step.

Cell Design Labs is developing several preclinical product candidates, including therapies for prostate cancer and hepatocellular carcinoma that use the synNotch technology. The company says that these technologies are able to engineer cells that are better able to recognize cancer, and in turn, spare healthy tissue.

"This acquisition demonstrates our deep commitment to continuing to invest in future innovation in the field of cellular therapy, both internally and externally", said Gilead CEO John Milligan in a December 7 statement. That's significant because the Kite CAR-T, which was approved to treat cases of non-Hodgkin lymphoma in patients who had failed two other treatments, comes with the risk of an immune response called cytokine release syndrome, in which inflammatory proteins called cytokines are activated in the body.

Share

Advertisement

Related Posts

Quantbot Technologies LP Buys New Holdings in MGIC Investment Corporation (MTG)
Moreover, Westfield Management Ltd Partnership has 0.4% invested in MGIC Investment Corporation (NYSE: MTG ) for 4.24M shares. Jane Street Gru Ltd Limited Liability Company owns 0% invested in MGIC Investment Corporation (NYSE: MTG ) for 31,969 shares.

Spot trends and buy/sell signals: Weyerhaeuser Company (WY), Danaher Corporation (DHR)
The company was maintained on Tuesday, April 19 by Citigroup. (NYSE:GNRT) on Thursday, October 19 with "Buy" rating. Riverpoint Mgmt Ltd Liability accumulated 6,064 shares or 0.04% of the stock. (NYSE:URI) for 108,739 shares.

Argentina beat India in Hockey World League Final semis
With this, Argentina, with the score being 1-0 against India, managed to reach their first ever final at the Hockey World League. The Indian coach, who generally watches re-runs of matches his side plays, said he wouldn't bother looking at this one.

What Analysts Have to Say About Ensco Plc (ESV)?
However, at one point, in the middle of the day, the price touched a high of $25.41 before it finally returned some of the gains. For the current quarter Ensco Plc (NYSE: ESV ) has high EPS estimates of $-0.02 in contradiction of low EPS estimates of $-0.6.

BB&T Corporation (BBT) Shares Sold by Stifel Financial Corp
By 23.24% BB&T Corporation EPS 23.24% will be on a par with past year, analyst expect per share earnings to be lower by 23.24%. The firm owned 93,686 shares of the insurance provider's stock after acquiring an additional 16,421 shares during the quarter.

Yankees, Brian Cashman close to new, five-year deal
The 50-year-old Cashman has been part of the Yankees organization since 1986, and he was promoted to general manager in 1998. The deal would give Cashman a significant raise, as his three-year, $9 million deal expired after the 2017 season.

Are Analysts Bearish Enbridge Energy Partners, LP (NYSE:EEP) After Last Week?
Silvercrest Asset Management Limited Co holds 0.11% of its portfolio in Spectra Energy Partners, LP (NYSE:SEP) for 236,586 shares. Mizuho restated a "hold" rating and set a $17.00 target price on shares of Enbridge Energy in a report on Friday, October 20th.

The "RuPaul's Drag Race" Queens Invade "America's Next Top Model" Cycle 24
It's also been announced that former judge Nigel Barker and season 3 victor of ANTM , Eva Marcille , will make guest appearances. With Drag Race on VH1 now it makes sense to have the queens shanté onto the network's other franchises.

Stifel Nicolaus Cuts Targa Resources (NYSE:TRGP) Price Target to $51.00
Targa Resources Corp . has a beta of 1.41, offering the possibility of a higher rate of return, but also posing more risk. Profund Advisors LLC boosted its position in shares of Targa Resources by 3.6% in the second quarter.

Dave & Buster's Entertainment's (PLAY) Buy Rating Reaffirmed at Canaccord Genuity
Staying on top of longer-term price action may help provide investors with a wider range of reference when doing stock analysis. Among 10 analysts covering Dave & Buster's Entertainment (NASDAQ: PLAY ), 9 have Buy rating, 0 Sell and 1 Hold.

© 2015 ExpressNewsline. All Rights reserved.